anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Non-gelatinous protein hydrolysate suitable for parenteral use is lyophilized in aqueous solution containing, in addition to the protein hydrolysate, a gelatin hydrolysate having a gel point of 15 to 20 DEG C. in 26 to 35% aqueous solution and being present in a ratio of 1 to 2 parts of gelatin hydrolysate to 9 parts of the non-gelatinous protein hydrolysate; it is stated that the foaming problem normally encountered does not become apparent to any appreciable extent when the partially hydrolysed gelatin is included. The gelatin hydrolysate may be made by hydrolysing an aqueous solution of gelatin for three hours at approximately 250 DEG F. and 15 lbs. per sq. inch pressure.  According to an example, to 1,470 ml. of 23% casein hydrolysate in which 69% of the total nitrogen was in the form of a -amino nitrogen, there was added 188 ml. of hydrolysed gelatin prepared as described above and containing 32% solids. Vitamins &amp;c., dextrose and sodium ethyl mercurithiosalicylate were added and the total volume of the solution was brought up to 3,08 litres with warm pyrogenfree distilled water.  After filtering, 77 ml. portions of the solution filled into 250 ml. brown-glass bottles were frozen at -60 DEG F. and then placed in a lyophiliser, the pressure being decreased to 50-150 microms.  The bottles were finally removed from the lyophiliser and aseptically stoppered.  The product, which contained less than 5% of moisture, reconstituted readily with pyrogen-free distilled water.  Other examples are concerned with lyophilising bovine plasma and fibrin hydrolysates.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for proliferating a spermatogonial stem cell in which influence of uncertain factor is eliminated.  &lt;P&gt;SOLUTION: The method for proliferating the spermatogonial stem cell comprises culturing the spermatogonial stem cell in feeder-free or serum-free condition. The spermatogonial stem cell can efficiently be proliferated even in the absence of a feeder cell or serum and influence of uncertain factor can be eliminated by using the proliferation method. As a result, the spermatogonial stem cell can more stably and more simply be proliferated in a state in which ability as the spermatogonial stem cell is kept, compared with a conventional method. Risk of infectious disease derived from a heterozoic in clinical application of the spermatogonial stem cell. Consequently, the proliferation method is useful for preparation of gene-modified animals (transgenic animal, gene deletion animal, etc.), a method for treating male sterility, development of therapeutic agent of male sterility and research for gene therapy in germ cell level and development, etc., of medicines.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention relates to a traditional Chinese medicine for treating anorexia. The traditional Chinese medicine can be used for effectively solving the problem that the anorexia in children is long in treatment period, poor in treatment effect and easily relapses. The traditional Chinese medicine for treating anorexia is prepared from the following medicinal raw materials by weight: 8-10g of codonopsis pilosula, 11-13g of Chinese yams, 5-7g of fructus amomi, 11-13g of coix seeds, 11-13g of chicken&#39;s gizzard-membranes, 8-10g of fructus aurantii, 11-13g of white atractylodes rhizome, 8-10g of poia cocos, 8-10g of dried tangerine or orange peel, 11-13g of roasted malts, 11-13g of hawthorns, 11-13g of medicated leaven, 11-13g of oysters, 8-10g of pangolins and 8-10g of tortoise plastron. A preparation method of the traditional Chinese medicine for treating anorexia comprises the following steps: mixing the medicinal raw materials, adding water to immerse the medicinal raw materials, decocting, firstly boiling with strong fire, then decocting with slow fire, filtering to obtain primary decoction; adding water to immerse dregs, boiling the dregs with strong fire, then, decocting the dregs with slow fire, and filtering to obtain secondary decoction; and mixing the decoctions to obtain the traditional Chinese medicine for treating anorexia. The traditional Chinese medicine for treating anorexia is scientific in compatibility of medicinal raw materials, simple in preparation method, short in treatment period, good in effect, free of side effect. Anorexia hardly relapses, and therefore, the traditional Chinese medicine for treating anorexia is a creation in the traditional Chinese medicine.
Embodiments include methods and systems for regulating a user&#39;s glucose levels. Systems comprise a processing unit in communication with a glucose monitor, an accelerometer, and a user interface. The glucose monitor generates glucose readings corresponding to the user&#39;s glucose levels and the accelerometer generates acceleration readings corresponding to the user&#39;s activity. The processing unit determines if the glucose readings indicate a glucose state and whether the acceleration readings indicate an activity state. If the glucose state and the activity state coincide, the processing unit sends a message to the user interface recommending a behavior that would influence the user&#39;s glucose level. Methods comprise determining, at a processing unit, if glucose readings indicate a glucose state, if acceleration readings indicate an activity state, whether the glucose state and activity state coincide and, if so, sending a message to a user interface recommending a behavior that would influence the user&#39;s glucose level.
The present invention was carried out to investigate the protective effect of Saussurea involucrate and Rutin against D-galactose (D-gal)-induced brain injury in mice. Protein expression was determined by Western blot. Apoptotic cells was determined by H &amp; E stain. D-galactose aging animal treatment was used as a model system to study the anti-oxidant effects of Saussurea involucrate and Rutin in vivo. Pretreatment with Saussurea involucrate and Rutin increased cell viability and decreased membrane damage, generation of reactive oxygen species and degradation of poly (ADP-ribose) polymerase in D-galactose-treated mice and also decreased the expression of cyclooxygenase-2, via downregulation of NF-kappaB, resulting in a decrease in lipid peroxidation. These results suggest that Saussurea involucrate and Rutin are potential antioxidant agents. In another set of experiments, we evaluated the effect of Saussurea involucrate and Rutin in a murine aging model, in which chronic systemic exposure to D-galactose (D-gal) causes the acceleration of senescence. Administration of Saussurea involucrate and Rutin (30 mg/kg/d and 10 mg/kg/d) for 6 weeks concomitant with D-gal injection significantly increased superoxide dismutase and glutathione peroxidase activities and decreased the MDA level in plasma and brain. Furthermore, we used H &amp; E staining to quantify cell death within hippocampus: counting of pyknotic nuclei in H &amp; E section. The result showed that percentage of pyknotic nuclei in the D-gal-treated mice were much higher than in control. These results suggest that Saussurea involucrate and Rutin exerts potent antiaging effects against D-gal in mice via antioxidative mechanisms.
A single point mutation in the human lipoprotein lipase gene which results in an A-&gt;G nucleotide change at codon 291 (nucleotide 1127) of the lipoprotein lipase gene, and a substitution of serine for the normal asparagine in the lipoprotein lipase gene product is seen with increased frequency in patients with coronary artery disease, and is associated with an increased susceptibility to coronary artery disease, including in particular premature atherosclerosis. This is expressed as a diminished catalytic activity of lipoprotein lipase, lower HDL-cholesterol levels and higher triglyceride levels. Thus, susceptibility of a human individual to premature atherosclerosis can be evaluated by:(a) obtaining a sample of DNA from the individual; and(b) evaluating the sample of DNA for the presence of nucleotides encoding a serine residue as amino acid 291 of the lipoprotein lipase gene product. The presence of a serine residue is indicative of increased susceptibility in the patient. This method may be performed using a kit which contains a pair of primers selected to amplify a region of a human lipoprotein lipase gene spanning amino acid 291 of human lipoprotein lipase. Appropriate additional reagents may also be included in the kit such as polymerase enzymes, nucleoside stock solutions and the like. Patients found to be suffering from or likely to suffer from premature atherosclerosis and other forms of coronary artery disease as a result of a lipoprotein lipase deficiency can be treated using gene therapy. This may be accomplished using adenovirus-mediated or retrovirus-mediated gene therapy, and can be performed using either an in vivo or an ex vivo approach.
Myofascial pain syndrome (MPS) is initial to other pathologies such as neck pain or tension headaches; the symptoms that are located on the area of myofascial trigger points (MTrPs) of specific references in different muscles. MTrPs are palpable, tense bands found in stiff muscle that cause pain and swelling. They affect the disruptive soft tissues, resulting in deterioration of the muscle and fascia; effects that can be transferred further, through the myofascial chain to distant tissues, inducing the referred pain that is the main feature of MPS. MTrPs are treated with stretching, massage, analgesics, acupuncture, dry needling, electrical stimulation, and ultrasound. Percutaneous microelectrolysis (MEP®) is a new technique that uses galvanic current of low intensity and high density. Based on the previous reviews, the investigators consider that the use of MEP in individuals who have MTrPs in the trapezius is more effective than acupuncture treatment. Objectives: To assess the effect of MEP as a technique for treating pain in MTrPs of the trapezius muscle compared to without current emission, analyzing function, pain and strength in MTrPs before and after both treatments.

Materials and methods: Randomized controlled clinical research. The study population consists of patients of both sexes between 20 and 60 years of age, with medical referral for neck pain who do not currently receive physiotherapeutic treatment, pain of at least 1 month of evolution, presenting on both sides of the trapezius MTrPs muscle and having signed the informed consent. They will be randomly distributed into: group treated with acupuncture (control) and group treated with MEP. Both will take place over 3 weeks, with one session per week. The evaluation is carried out through the visual analogue scale (VAS), measurement of force with a dynamometer and mobility with a goniometer. The score will be recorded on a validated neck pain questionnaire (NPQ). The Chi-Square test (test) will be implemented for the analysis of categorical data and the \&quot;t\&quot; test for paired data for quantitative data, based on a significance level of p˂0.05 in all cases.
PROBLEM TO BE SOLVED: To readily and efficiently obtain an intraoral disintegrant which shows sufficient strength and fine intraoral disintegration and causes no decrease of the strength even under high humidity by leaving a specific tablet containing amorphous lactose under a relative humidity in the specific range and converting the amorphous lactose into crystalline lactose. SOLUTION: The objective preparation is obtained by leaving a tablet, which contains amorphous lactose in a proportion of about 5-40 wt.%, preferably about 10-30 wt.%, and is molded under a low pressure of about 50-300 kg/cm&lt;2&gt; , at preferably about 15-50 deg.C for 1-24 hours under a relative humidity of about 60-90%, preferably about 70-85%, and converting the amorphous lactose into the crystalline lactose. The above amorphous lactose is usually obtained by preparing a solution of alpha 1 hydrated crystalline lactose or the like and then treating the solution by means of lyophilization or the like. Preferably about 0.1-10 wt.%, of a medicine, e.g. citric acid mosapride citrate or the like, or usually about 50-90 wt.% of a vehicle, e.g. mannitol or the like, are included in the above tablet.
Technologies are disclosed for detection and display of an indication of a gingivitis condition and/or a periodontal pocket assessment of a subject&#39;s oral cavity via a digital representation of the oral cavity. Using scan data of the oral cavity, one or more teeth in the oral cavity may be indicated. A first assessment location proximate to a first tooth of the one or more teeth may be indicated. A first image may be generated that may include the first assessment location and one or more first data channels. The one or more first data channels may comprise color data and topological information corresponding to the first assessment location. Using one or more machine-learning algorithms, a modified gingival index (MGI) value and/or a periodontal pocket depth assessment may be determined and displayed for the first assessment location based on the first image and the one or more first data channels.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an oxidation hair dye composition having excellent dyeability and fastness to shampooing.  &lt;P&gt;SOLUTION: This oxidation dye composition having the excellent dyeability and fastness to shampooing can be obtained by formulating an amino acid or its salt in an oxidation hair dye-containing p-phenylenediamine. The amino acid used herein is not especially limited if the amino acid is used. The amino acid preferably has sulfur and includes, e.g. cystine, cysteine and methionine, more preferably cysteine. When monoethanolamine is formulated, there has been disadvantages such as poor dyeability and fastness to shampooing. However, by this invention, merchandise satisfactory to the dyeability and fastness to shampooing can be provided without being annoyed with an irritant order.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
FIELD: medicine, mycology, dermatology. SUBSTANCE: one should use a solution as antimicrobial product. To prepare this solution it is necessary to grind 14 tablets of lamysil to obtain powder-like state, then they are poured with 100 ml 1%-dimexide solution, the mixture obtained should be kept for 1 d in sealed dark glass-made vial, then 100 ml 70%-acetic acid should be added together with 100 ml 5%-iodine solution. Then the solution obtained should be applied upon nail laminae and nail-walls once daily, and upon feet&#39;s skin -twice weekly for 6 mo. The present method leads to higher efficiency of therapy due to increased percentage of clinicolaboratory healing of onychomycosis and prevents the development of disease relapses. EFFECT: improved results of therapy.
Production of an anticancer agent based on lanthanides (esp. oxides of lanthanides) comprises (a) growing a single crystal of lanthanides (esp. oxides of lanthanides or mixtures of such oxides), (b) macerating the single crystal to a particle size of is not &gt; 7 mu m, and (c) bringing the macerated crystal into an aqueous, physiological suspension. The agent is effective against all kinds of cancer. It is injected into the bloodstream and the cancer tumour is immediately irradiated with relatively soft X-rays. This causes positive quantum energy to be released in the crystals. The energy is transferred to the negatively charged tumour, causing the potential drop across the tumour cell membrane to return to normal, so that the tumour cells are converted back into normal cells. Thus, unlike conventional anticancer treatment, the new treatment converts cancer cells into normal cells rather than destroying them.
PURPOSE:To provide the titled crystallized glass most suitable as an artificial bone and a dental material by composing the glass of the oxide of Cu, Li, La, Gd, Ti, Sm, Nb, Zr, or Ru and specified calcium phosphate, vitrifying, and then crystallizing the material. CONSTITUTION:The glass consists of 0.1-30wt% &gt;=1 kind of oxide selected from the oxide of Cu, Li, La, Gd, Ti, Sm, Nb, Zr, and Ru and the remainder of calcium phosphate whose atomic ratio of calcium to phosphorus is regulated to 0.35-1.7, and the material is vitrified, then heat-treated and crystallized. When the content of the oxide is regulated to &lt;0.1wt%, the effect is not fully exhibited, because the crystallization proceeds mostly with devitrification on the surface. Meanwhile, when the content is regulated to &gt;=30wt%, the m.p. is gradually increased, the viscosity is also increased, and the moldability is unfavorably effected. When said atomic ratio exceeds the value of 1.7, the m.p. is raised, and the material is not vitrified. Meanwhile, when the ratio is lower than 0.35, crystallization becomes difficult, and the material is unfavorably made chemically unstable.
This invention is for an improved method of treating hyperkinetic behavior based on the discovery of the etiology of the disorder. The genesis of the invention is in the discovery that constant overactivity, distractibiity, impulsiveness, and aggressiveness, is frequently related to hypoglycemia. It has been discovered that hyperkinetic behavior due to moderate hypoglycemia will respond favorably, to the treatment of hypoglycemia. Hypoglycemia occurs during fasting and is due to an inappropriate presence of serotonin at the liver. Serotonin is a key hormone in conjunction with insulin to program liver glucose control. From this, the method is described of using a serotonin antagonist or an agent to block synthesis and/or storage of serotonin after glucose is no longer supplied to the portal vein. Then the liver can cease glucose uptake and begin production of glucose for the peripheral blood supply. The preferred serotonin antagonist is cyproheptadine. 
     Increased blood serotonin levels, in a fasting state, causes hepatic retention of glucose and a degree of hypoglycemia. The body corrects the hypoglycemia by activating the adrenergic nervous system. Adrenergic correction of hypoglycemia is followed by regression, then adrenergic correction again on and on in prolonged cycle. The adrenergic correction is associated with overactivity and behavioral (characteristics associated with the well known &#34;fight and flight&#34; response). Although the activity lessens as a child grows older, and often disappears by adolescence, some mental disorders are probably the result of prolonged mild hypoglycemia.
The invention discloses a preparation method of a porcine TLR4 polyclonal antibody. According to the preparation method, recombinant TLR4 protein (antigen) and freund&#39;s adjuvant are emulsified, then an immune animal obtains polyclonal antibody serum, wherein the recombinant TLR4 protein has the amino acid sequence as indicated in the sequence table SEQ. ID. No. 1. It is shown through tests that the antibody prepared through the method is good in reactivity and specificity; due to the fact that a TLR4 gene is a member of a significant pattern recognition receptor Toll-like receptor family targeted to innate immune response, the porcine TLR4 polyclonal antibody can be applied to detection of the porcine TLR4 protein and related research; a good foundation is laid for researching the interaction mechanism between porcine bacterial and viral infection diseases and TLR4 and the virus immunity escape mechanism, and a new target is provided for developing new generation vaccine and medicine. Meanwhile, a prokaryotic expression vector constructed through the method is high in recombinant protein expression efficiency, and the separation and purification method is simple and easy to operate.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide methods and compositions for treating or preventing cancers.  &lt;P&gt;SOLUTION: The present invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application. A method for treating or preventing a medical condition, in a subject, selected from the group consisting of neuroblastoma, rhabdomyosarcoma, Wilm&#39;s tumor, osteosarcoma, pancreatic cancer and pediatric cancers. The method includes a step of administering a therapeutically effective amount of one or more IGF1R inhibitors or pharmaceutical compositions thereof to the subject.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To impart excellent damage repairing effects on hair, receiving chemical damage with a hair dye or perming, etc., to a hair cosmetic by repairing from the outside.  &lt;P&gt;SOLUTION: A treatment frequently using a protein hydrolyzate such as supplementation of the protein hydrolyzate having high hair repairing effects or formation of a film from a product prepared by silylating the protein hydrolyzate on the surface of hair to improve the texture of the hair is conventionally a well-known fact. It is however hard to say that the treatment is satisfactory in the repairing effects on defective settlement resulting from hair damage. As a result of various studies made on quaternized polymers, good effects imparting excellent conditioning effects such as impartment of good retention to the hair, a reduction in chemical damage with the hair dye or perming, etc., a reduction in floating with static electricity or a reduction in frizz are found out by formulating a quaternized corn starch. Thereby, development is made.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:A supplementary electrolytic solution not precipitating even at a physiological pH, useful for remedying hypomagnesemia accompanied by hepatic disease or diabetes, obtained by adding citric acid or its salt to a supplementary electrolytic solution containing an Mg salt and a phosphate. CONSTITUTION:An Mg salt (e.g., MgCl2, magnesium carbonate, etc.) and a phosphate (e.g., sodium dihydrogenphosphate, disodium hydogenphosphate, etc.) are blended with citric acid or its salt, to give a supplementary electrolytic solution supplying Mg ion or phosphate ion, not precipitating even at a physiological pH. In the operation, it is required to make a molar ratio of citric acid to Mg salt &gt;=0.05. An Mg salt and phosphate form a slightly soluble salt in an aqueous solution at a physiological pH, but the addition of citric acid or its salt prevents the solution from precipitating.
Methods and systems are described for generating a shipping label for an item to be shipped using a wireless node network. The network includes a master node associated with a shipping facility, a node associated with a shipping customer, and a server. The master node receives shipping information from the server, where the shipping information is related to the node associated with the shipping customer and item to be shipped. The master node then detects a signal from the shipping customer&#39;s node as it approaches the shipping facility. The master node proceeds to become associated with the shipping customer&#39;s node. The master node then causes generation of the shipping label for the item to be shipped when the master node determines the node associated with the shipping customer is within a predetermined range of a location within the shipping facility.